Biolidics Limited (SGX:8YY)

Market Cap	37.20M
Revenue (ttm)	858.00K
Net Income (ttm)	-3.43M
Shares Out	1.69B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	351,000
Average Volume	1,173,330
Open	0.0220
Previous Close	0.0210
Day's Range	0.0220 - 0.0230
52-Week Range	0.0080 - 0.0330
Beta	0.51
RSI	49.50
Earnings Date	Aug 28, 2025

About Biolidics

Biolidics Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions in Japan, Hong Kong, Thailand, Malaysia, and the United States. It operates through Cancer, Infectious Diseases, and Laboratory Services segments. The company offers ClearCell FX1 System that includes Streck Cell-free DNA BCT and EDTA tubes, a fully automated device for cell retrieval that can separate wholly intact and viable circulating tumour cells, or CTCs from small amounts of blood; and CTChip FR1 biochip that isol...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2009
• Employees: 7
• Stock Exchange: Singapore Exchange - Catalist
• Ticker Symbol: 8YY

Financial Performance

In 2024, Biolidics's revenue was 858,000, an increase of 176.77% compared to the previous year's 310,000. Losses were -3.43 million, 38.0% more than in 2023.